Cosentyx And Entresto Keep Powering Novartis As Firm Mulls Sandoz Sale
Sales Forecasts Lifted For Top Two Earners
CEO Vas Narasimhan sees Novartis very much as an innovative company so the long-awaited strategic review of Sandoz suggests that the generics/biosimilars business could be spun off or sold fairly soon.
